Clinical Trials

Find a Trial

Trial Results

11 protocol(s) meet the specified criteria
ARRAY818-302OPEN TO ACCRUAL
The BEACON CRC Study (Binimetinib, Encorafenib, And Cetuximab COmbiNed to Treat BRAF-mutant ColoRectal Cancer): A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA) /Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer
BAY94-9343OPEN TO ACCRUAL
Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY 94-9343)in Patients with Mesothelin Expressing Advanced or Recurrent Malignancies
BBI-DSP0337-101OPEN TO ACCRUAL
A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0337, a Cancer Stemness Inhibitor, in Patients with Advanced Solid Tumors
BTCRC-GI13-002OPEN TO ACCRUAL
An Open Label Randomized Phase I/II Trial of MLN0128 Compared to Sorafenib in Patients with Advanced or Metastatic Hepatocellular Carcinoma: Big Ten Cancer Research Consortium BTCRC-GI13-002
CANSTEM111POPEN TO ACCRUAL
A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma.
CTMX-M-2009-001OPEN TO ACCRUAL
A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors
I9L-MC-JZCAOPEN TO ACCRUAL
A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination with Anti- PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors
IUCRO-0495OPEN TO ACCRUAL
Creation of a Pancreatic Cancer Outcome Database with Blood Storage
IUSCC-0597OPEN TO ACCRUAL
A phase II trial of cabozantinib and erlotinib for patients with EGFR and c-Met co-expressing metastatic pancreatic adenocarcinoma
LCCC1317OPEN TO ACCRUAL
Genotype-directed Phase II Study of Irinotecan Dosing in Metastatic Colorectal Cancer (mCRC) Patients Receiving FOLFIRI + Bevacizumab
MS100015-0019OPEN TO ACCRUAL
An Open-label, Phase I, Dose Escalation Trial of Methionine Aminopeptidase 2 Inhibitor M8891 in Subjects with Advanced Solid Tumors